Begin main content

News and Events

Latest News

Therapeutic Review of Third-Line Drugs for Type 2 Diabetes — An Update

January 26, 2018
In 2017, CADTH began preliminary work on a Therapeutic Review to assess new third-line drug therapies for type 2 diabetes and provide recommendations on their optimal use. The drugs included in this review included dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 analogues, and sodium-glucose cotransporter-2 inhibitors. In January 2018...

Call for Patient Input: Orkambi

January 24, 2018
CADTH has received the following drug submission(s) and/or notice(s) of pending submission(s). If you are interested in providing patient input, please click on “Submit.” For information about the patient input process or for additional instructions, please see the Patient Input page of our website. Orkambi Brand name Generic name Manufacturer I...

Call for Feedback: Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism

January 22, 2018
A draft report on Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism is now available for feedback from all interested stakeholders. Project Call for Feedback Feedback Due By Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism 2018-01-22 2018-02-06 Consultation Document Product Type Submit Stakeholder Feedback Draft Re...

Upcoming Events

HTAi 2018 Annual Meeting

June 1, 2018 - June 5, 2018
CADTH is pleased to be co-hosting the Health Technology Assessment international (HTAi) 2018 Annual Meeting in Vancouver, British Columbia, June 1 to 5, 2018. Dr. Tammy Clifford, Chief Scientist and Vice-President of Evidence Standards and Medical Devices at CADTH, is a co-chair of the International Scientific Programme Committee. The theme of t...